LRRC32 and cancer: So, for example, by pinpointing the exact GARP/TGFβ:LAP interface with mAb therapy, it is now possible to interfere with the local immune-suppressive TGFβ1-mediated effects of Tregs within a tumor, thus promoting PD-1/PD-L1–based immune activation in cancer immunotherapy.8 This also means that during transplantation, the gathering of Tregs and Bregs within the graft and their exosomal TGFβ:LAP/GARP release may benefit the patient undergoing withdrawal or minimization of immunosuppressive drug therapy by propagating local IS.